Stereotaxis Acquires Robocath

Enovis to Acquire eCential Robotics

September 1, 2026

Medical Devices

Enovis entered a binding offer to acquire eCential Robotics for an upfront enterprise value of €155 million, with approximately €176 million in cash consideration and up to €35 million in contingent milestone payments. The proposed acquisition adds eCential’s orthopedic surgical robotics, navigation technology, engineering expertise, and intellectual property to Enovis’ ASTRA platform; it is expected to close by year-end 2026, subject to required processes and regulatory approvals.

Medtronic Completes Acquisition of CathWorks

April 20, 2026

Medical Devices

Medtronic plc has completed its acquisition of CathWorks, a privately held medical device company focused on transforming how coronary artery disease is diagnosed and treated. The deal is valued at $585 million, with potential undisclosed earn-out payments, and enhances Medtronic’s interventional cardiology portfolio via the CathWorks FFRangio System.

Medtronic to Acquire Scientia Vascular

March 10, 2026

Medical Devices

Medtronic entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal, with customary adjustments and potential earn-out/milestone payments. The acquisition combines Scientia’s neurovascular access devices (guidewires and catheters) with Medtronic’s existing neurovascular therapeutic portfolio to support faster and more reliable treatment for complex stroke cases.

Stereotaxis Acquires Access Point Technologies (APT)

May 13, 2024

Medical Devices

Stereotaxis (NYSE: STXS) entered into a definitive share purchase agreement to acquire Access Point Technologies (APT), a Minnesota-based developer and manufacturer of electrophysiology (EP) diagnostic catheters. The deal consideration is payable in Stereotaxis common stock (upfront plus contingent milestone payments); Stereotaxis said APT is expected to contribute roughly $5 million of revenue in the first year and the acquisition is intended to add catheter development and manufacturing capabilities to accelerate EP and robotic endovascular offerings.

Cirtec Medical Acquires NovelCath

December 17, 2020

Medical Devices

Cirtec Medical Corporation has acquired NovelCath, a vertically integrated manufacturer of catheter delivery systems based in Brooklyn Park, Minnesota. The acquisition expands Cirtec's capabilities in minimally invasive interventional and structural heart device manufacturing and establishes the NovelCath facility as Cirtec's Center of Excellence for Catheters and Delivery Systems.

StemBioSys Acquires Majority Stake in Cartox

January 8, 2020

Biotechnology

San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.